Efficacy News and Research

RSS
Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

Tiny tumbling soft robots could precisely deliver drugs to central nervous system

Tiny tumbling soft robots could precisely deliver drugs to central nervous system

New platform can quickly identify common mutations on the SARS-CoV-2 virus

New platform can quickly identify common mutations on the SARS-CoV-2 virus

Penn study discovers a targetable vulnerability in clear cell renal cell carcinoma

Penn study discovers a targetable vulnerability in clear cell renal cell carcinoma

Pilot study assesses antibody response to third COVID-19 vaccine dose in kidney transplant recipients

Pilot study assesses antibody response to third COVID-19 vaccine dose in kidney transplant recipients

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

Evaluation of COVID-19 risk among international travelers in the UK for safety purposes

Evaluation of COVID-19 risk among international travelers in the UK for safety purposes

Children's Hospital Colorado announces participation in pivotal trial of synthetic restorative pulmonary valve

Children's Hospital Colorado announces participation in pivotal trial of synthetic restorative pulmonary valve

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

New study receives $33 million PCORI funding to compare anesthetic medications

New study receives $33 million PCORI funding to compare anesthetic medications

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

Quanterix Simoa® Technology Powers Breakthrough Alzheimer’s Disease Research Presented by Eli Lilly and Company at Alzheimer’s Association International Conference (AAIC) 2021

Study of antibody responses to COVID-19 mRNA vaccine in convalescent individuals

Study of antibody responses to COVID-19 mRNA vaccine in convalescent individuals

New compound inspired by tapeworm drugs shows two-pronged effectiveness against COVID-19

New compound inspired by tapeworm drugs shows two-pronged effectiveness against COVID-19

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

Surfactant-coated nanoparticle applications in nanomedicine and food

Surfactant-coated nanoparticle applications in nanomedicine and food

Oral drug found to be effective, safe for treating anemia in patients with chronic kidney disease

Oral drug found to be effective, safe for treating anemia in patients with chronic kidney disease

Online training leverages the influence of religion to prevent intimate partner violence

Online training leverages the influence of religion to prevent intimate partner violence

Topical cream shows signs of clinical efficacy in patients with basal cell carcinoma

Topical cream shows signs of clinical efficacy in patients with basal cell carcinoma

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

Aducanumab approval for Alzheimer's may provide a proof of concept that can be rapidly improved upon

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.